Moreover, indirect inhibition of PRMT1, as well as targeting the PTM of cGAS, can be combined with each other or with immune checkpoint blockade for effective strategy to enhance the anti-tumor immunity of cancer cells. This evidence concerns the gene PRMT1 and neoplasm.